Polyrizon Ltd. has finished the branding process for its PL‑14 allergy blocker, which will be sold under the new name NASARIX™. The product is built on the company’s proprietary Capture and Contain™ hydrogel platform, designed to form a physical barrier that blocks allergens and viruses when applied intranasally.
Continue reading for full analysis...
Polyrizon Ltd. (Nasdaq: PLRZ) reported that its PL‑14 Allergy Blocker hydrogel spray achieved a statistically significant reduction in house dust mite allergen (Der p 1) transfer in a new in‑vitro Transwell permeability study. Compared with hydroxypropyl methylcellulose (HPMC), the standard nasal barrier comparator, PL‑14 reduced Der p 1 concentrations at every tested time point—1, 2, 4, 6, and 24 hours—with p‑values of 0.0042 or lower. At 1 hour, mean Der p 1 levels were 20.6 ng for PL‑14 versus 1,354.4 ng for HPMC; at 24 hours, the levels were 141.2 ng for PL‑14 compared with 5,201.2 ng for HPMC.
Continue reading for full analysis...
Polyrizon Ltd. (Nasdaq: PLRZ) announced that its Board of Directors has authorized a new strategic initiative to explore revenue‑generating real‑asset opportunities. The move is intended to leverage the company’s strong cash position and debt‑free balance sheet while the company continues to advance its intranasal hydrogel platform, including PL‑14, PL‑16 and the Trap & Target drug‑delivery technology.
Continue reading for full analysis...
Polyrizon Ltd. filed a Pre‑Request for Designation with the U.S. Food and Drug Administration for its PL‑16 Viral Blocker, a non‑pharmacological intranasal spray that creates a physical hydrogel barrier to reduce exposure to influenza and other cold viruses.
Continue reading for full analysis...